RecruitingNCT05741073

Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC

Sponsor

EuMelaReg gGmbH

Enrollment

1,300 participants

Start Date

Jun 30, 2023

Study Type

OBSERVATIONAL

Conditions

Cutaneous Squamous Cell Carcinoma Basal Cell Carcinoma

Summary

This current registry study will analyze real-world data to address questions about disease characteristics and treatment patterns in NMSC patients based on the European NMSC-Registry. The overall objective is to describe characteristics, management and treatment outcomes for patients presenting with advanced NMSC (cSCC/BCC) or HR-cSCC in routine clinical practice, independent of treatments used across different European regions.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Patients aged ≥18 years at index date
Patients documented in the European NMSC-registry fulfilling EMR quality standard
Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)